Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Giant dentinogenic ghost cell tumor: A case report

Texto completo
Autor(es):
Soares, Ciro Dantas [1] ; Carlos, Roman [2] ; de Lima Morais, Thayna Melo [1] ; de Almeida, Oslei Paes [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, UNICAMP, Dept Oral Diag, Piracicaba Dent Sch, Piracicaba, SP - Brazil
[2] Hosp Herrera Llerandi, Ctr Clin Cabeza & Cuello, Pathol Div, Guatemala City - Guatemala
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY; v. 126, n. 4, p. E215-E219, OCT 2018.
Citações Web of Science: 0
Resumo

Dentinogenic ghost cell tumor (DGCT), a rare, benign odontogenic tumor with aggressive behavior, causes bone destruction and cortical expansion. We report here a case of DGCT in a 38-year-old male, presenting with enormous extraoral protrusion, which radiographically was predominantly radiolucent with radiopaque areas. Microscopically, it was observed to be a solid ameloblastomatous proliferation with pseudoglandular structures associated with clusters of ghost cells. Abundant dentinoid material adjacent to the epithelial sheets containing entrapped epithelial tumor cells was also evident. lrnmunohistochernistry revealed positivity for pan-cytokeratin (CK), CK-14, CK-7, and CK-19; CD138; and beta-catenin. The Ki-67 proliferative index was very low (<1%). The clinical, histopathologic, and immunohistochemical features led to the diagnosis of DGCT. The patient underwent partial mandibulectomy, and no recurrences have occurred. To our knowledge, this is the largest DGCT described in the English language literature. (AU)

Processo FAPESP: 15/25905-1 - Expressão de Akt, COX-2, RUNX1 e metaloproteinases em melanomas metastáticos e Prospecção biotecnológica de moléculas com atividade antitumoral
Beneficiário:Ciro Dantas Soares
Modalidade de apoio: Bolsas no Brasil - Doutorado